Gates Foundation Invests Up to $40M in Immunocore to Develop TCR-Based Therapies

The Bill & Melinda Gates Foundation is investing up to $40 million in Immunocore to support development of the company’s soluble TCR (T-cell receptor)-based ImmTAV® (immune mobilising monoclonal TCRs against virus) and ImmTAB® (immune mobilising monoclonal TCRs against bacteria) therapeutics for infectious diseases that represent global health challenges. The organizations will focus on the development of ImmTav and ImmTAB molecules for treating tuberculosis (TB) and human immu